Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-01-06 DOI:10.1186/s12885-025-13440-5

Yusuke Hamakawa, Ayumi Hirahara, Akiko Hayashi, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Hiroaki Okamoto

{"title":"Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.","authors":"Yusuke Hamakawa, Ayumi Hirahara, Akiko Hayashi, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Hiroaki Okamoto","doi":"10.1186/s12885-025-13440-5","DOIUrl":null,"url":null,"abstract":"Introduction: The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use.Methods: Of 62 patients with SCLC who received chemoimmunotherapy at our institution between September 2019 and July 2024, we retrospectively analyzed 36 patients who subsequently received ICI maintenance therapy following the initial chemoimmunotherapy treatment. The SII was calculated at the start of the second cycle of the ICI maintenance therapy. Patients were stratified into high (≥ 570) and low (< 570) SII groups. Overall survival (OS) and progression-free survival (PFS) were compared between the groups using the Kaplan-Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to identify independent prognostic factors.Results: The high SII group exhibited a significantly shorter OS (median 12.1 vs. 24.1 months, P = 0.010) and PFS (median 5.2 vs. 8.1 months, P = 0.026) than those in the low SII group. A multivariate analysis identified SII ≥ 570 as an independent negative prognostic factor for OS (hazard ratio 3.83, 95% confidence interval 1.38-10.6, P = 0.010).Conclusions: Elevated SII in the initial phase of ICI maintenance therapy was associated a with poor prognosis in patients with SCLC, supporting its utility as a prognostic biomarker in this setting. Therefore, prospective validation is required to confirm these findings.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"17"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706134/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13440-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use.

Methods: Of 62 patients with SCLC who received chemoimmunotherapy at our institution between September 2019 and July 2024, we retrospectively analyzed 36 patients who subsequently received ICI maintenance therapy following the initial chemoimmunotherapy treatment. The SII was calculated at the start of the second cycle of the ICI maintenance therapy. Patients were stratified into high (≥ 570) and low (< 570) SII groups. Overall survival (OS) and progression-free survival (PFS) were compared between the groups using the Kaplan-Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to identify independent prognostic factors.

Results: The high SII group exhibited a significantly shorter OS (median 12.1 vs. 24.1 months, P = 0.010) and PFS (median 5.2 vs. 8.1 months, P = 0.026) than those in the low SII group. A multivariate analysis identified SII ≥ 570 as an independent negative prognostic factor for OS (hazard ratio 3.83, 95% confidence interval 1.38-10.6, P = 0.010).

Conclusions: Elevated SII in the initial phase of ICI maintenance therapy was associated a with poor prognosis in patients with SCLC, supporting its utility as a prognostic biomarker in this setting. Therefore, prospective validation is required to confirm these findings.

查看原文本刊更多论文

免疫检查点抑制剂治疗的小细胞肺癌患者全身免疫炎症指数的预后价值。

系统性免疫炎症指数（SII）已成为各种恶性肿瘤的预后指标。然而，其在接受免疫检查点抑制剂（ICIs）治疗的小细胞肺癌（SCLC）患者中的预后意义尚不清楚。在这项研究中，我们评估了使用ICI后SII对SCLC患者预后的影响。方法：对2019年9月至2024年7月期间在我院接受化疗免疫治疗的62例SCLC患者进行回顾性分析，其中36例患者在初始化疗免疫治疗后随后接受了ICI维持治疗。SII在ICI维持治疗的第二个周期开始时计算。患者被分为高（≥570）和低(结果：高SII组的OS（中位数12.1 vs. 24.1个月，P = 0.010）和PFS（中位数5.2 vs. 8.1个月，P = 0.026）明显短于低SII组。多变量分析发现SII≥570是OS的独立负面预后因素（风险比3.83,95%可信区间1.38-10.6,P = 0.010）。结论：在ICI维持治疗的初始阶段SII升高与SCLC患者预后不良相关，支持其作为预后生物标志物的效用。因此，需要前瞻性验证来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.